Rapid Reviews-I

Rapid Reviews-I By Shona Nag

Speaker :

Shona Nag

1. cfDNA analysis from BOLERO-2 plasma samples identifies a high rate ESR1 mutations: Exploratory analysis for prognostic and predictive correlation of mutations reveals different efficacy outcomes of endocrine therapy based regimens

Author: Chandarlapatys

Conference: SABCS

2. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in pstmenopausal women with endocrine-resistant HR+/HER2- advanced breast cancer (BC): First results from the randomized, Phase III BELLE-2 trial

Author: J. Baselga

Conference: SABCS

3. Effects of perioperative lapatinib in early HER2+ breast cancer – The UK EPHOS-B trial (CRUK/08/002)

Author: N. Bundred

Conference: SABCS

4. High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized Phase II study testing pictilisib (GDC-0914) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor(AI)

Author: S. Gendreau

Conference: SABCS

5. A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B31 for HER2+ breast cancer

Author: Seong-Rim Kim

Conference: AACR

6. P53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – A translational subproject of Gepar Sixto trial

Author: S. Darb-Esfahani

Conference: IMPAKT

7. Somatic BRCA 1 mutations determine different responses to platinum-based chemotherapy

Author: E. Ignatova

Conference: IMPAKT

8. Histology and molecular characteristics of pregnancy associated breast cancer

Author: Z. Tomasevic

Conference: IMPAKT

9. Evaluation of PDL1 expression in breast cancer by immunohistochemistry

Author: C. Solinas

Conference: IMPAKT

10. Targeting unique metabolic vulnerabilities in dormant ER & plus; tumor cells

Author: E. Knudsen

Conference: IMPAKT

11. Smart delivery of lapatinib to reduce its cardiotoxicity: A 99mTc labeled biodistribution study

Author: A. Khanna

Conference: IMPAKT

12. 230 Clinical patterns of metastatic spread from formal in fixed, paraffin-embedded (FFPE) expression profiles: A case-control study of 1,357 breast cancer patients

Author: K. Lawler

Conference: IMPAKT

13. Evolution from primary breast cancer to relapse and metastasis

Author: L. Yates

Conference: ASCO

14. The driver landscape of breast cancer metastasis and relapse. 2015 European Cancer Congress

Author: L. Yates

Conference: SABCS

15. Final updated results of the NRG Oncology/ NSABP ProtocolP2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer

Author:D.L. Wickerham

Conference: ASCO

16. Breast MRI screening of women at average risk of breast cancer: An observational cohort study

Author: Christiane K. Kuhl

Conference: ASCO Breast Symposium

17. Agreement in risk assessment among breast cancer specialists: A survey within the MINDACT cohort

Author: C. Drukker

Conference: IMPAKT

18. Male breast cancer receptor sub-types: Demographics, tumor characteristics and short term survival outcomes

Author: S. Yadav

Conference: IMPAKT

19. Examination of the sentinel lymph node identification in breast cancer combining contrast enhanced ultrasonography and the blue dye method without radioisotope

Author: K. Futsuhara


20. Association between HER2 phenotype on circulating tumor cells and primary tumor characteristics in women with metastatic breast cancer

Author: W. Janni

Conference: ESMO

21. Targeting HER2 in patients with HER2-negative metastatic breast cancer with elevated serum levels of the HER2 extracellular domain and/or HER2-positive circulating tumor cells in the clinical routine

Author: C. Kurbacher

Conference: IMPAKT